HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ZTS

Zoetis Inc. (S&P 500)

Healthcare — Drug Manufacturers - Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Buy 2.1 / 5 17 analysts
$77.51
+$0.59 (+0.77%)
Target: $111.94 (44.4%)
Sign in to add ZTS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$32.49B
P/E Ratio (TTM)12.71
Forward P/E10.49
EPS (TTM)$6.10
Dividend Yield2.76%
Profit Margin28.04%
Revenue Growth2.90%
ROE67.75%
Debt/Equity286.24
Recommendation Buy 2.1
Analyst Target$111.94
Analysts17
Indexes S&P 500

Technical Indicators

RSI (14)61.1
Beta0.75
SMA 20$75.21
SMA 40$76.78
52-Week High$160.48
52-Week Low$71.47
50-Day Avg$77.14
200-Day Avg$111.77
Avg Volume$7.52M
Volume$5.47M

Performance Analysis

BULLISH

ZTS shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($71.47), which could present a value opportunity.
+ RSI at 61.1 shows positive momentum.
+ P/E of 12.7 suggests the stock may be undervalued.
~ Modest revenue growth of 2.9% year-over-year.
+ Healthy profit margin of 28.0%.
+ Wall Street consensus is "Buy" from 17 analysts.
+ Average analyst target of $111.94 implies 44.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report